HRP20140880T1 - Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina - Google Patents
Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina Download PDFInfo
- Publication number
- HRP20140880T1 HRP20140880T1 HRP20140880AT HRP20140880T HRP20140880T1 HR P20140880 T1 HRP20140880 T1 HR P20140880T1 HR P20140880A T HRP20140880A T HR P20140880AT HR P20140880 T HRP20140880 T HR P20140880T HR P20140880 T1 HRP20140880 T1 HR P20140880T1
- Authority
- HR
- Croatia
- Prior art keywords
- salt
- lactic acid
- addition
- additional
- liquid formulation
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 36
- 239000012669 liquid formulation Substances 0.000 title claims 10
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical class CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title claims 6
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical class C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 13
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical class C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229960000448 lactic acid Drugs 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 229930182843 D-Lactic acid Natural products 0.000 claims 4
- 229940022769 d- lactic acid Drugs 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000035764 nutrition Effects 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Lubricants (AREA)
Claims (22)
1. Tekuća farmaceutska formulacija koja obuhvaća sol 1-[2-(2,4 dimetilfenilsulfanil)fenil]piperazina izabrana između dodatka soli DL-mliječne kiseline, dodatka soli L-mliječne kiseline i dodatka soli D-mliječne kiseline.
2. Tekuća formulacija u skladu s patentnim zahtjevom 1, pri čemu je navedena sol dodatna sol DL-mliječne kiseline.
3. Tekuća formulacija u skladu s patentnim zahtjevom 1, pri čemu je navedena sol dodatna sol L-mliječne kiseline.
4. Tekuća formulacija u skladu s patentnim zahtjevom 1, pri čemu je navedena sol dodatna sol D-mliječne kiseline.
5. Tekuća formulacija u skladu s bilo kojim od patentnih zahtjeva 1-4, pri čemu je koncentracija navedene soli iznad 2.5 mg/mL.
6. Uporaba soli 1-[2-(2,4 dimetilfenilsulfanil)fenil]piperazina izabrane između dodatka soli DL-mliječne kiseline, dodatka soli L-mliječne kiseline i dodatka soli D-mliječne kiseline u proizvodnji tekuće formulacije za liječenje bolesti odabrane između poremećaja raspoloženja; značajnog depresivnog poremećaja; općeg anksioznog poremećaja; paničnog poremećaja; posttraumatskog stresnog poremećaja; depresije povezane s kognitivnim nedostatkom, Alzheimerove bolesti ili tjeskobe; depresije s ostatnim simptomima; kronične boli; poremećaja ili zlouporabe prehrane, pri čemu je navedena sol u tekućoj formulaciji.
7. Uporaba u skladu s patentnim zahtjevom 6, pri čemu je navedena sol dodatna sol DL-mliječne kiseline.
8. Uporaba u skladu s patentnim zahtjevom 7, pri čemu je navedena sol β oblik dodatne soli DL-mliječne kiseline karakterizirana XRPD refleksijama na 6.01, 10.10, 10.32, 12.06, 12.84, 13.08 i 13.58 (°2Ѳ).
9. Uporaba u skladu s patentnim zahtjevom 6, pri čemu je navedena sol dodatna sol L-mliječne kiseline.
10. Uporaba u skladu s patentnim zahtjevom 9, pri čemu je navedena sol MH 2 oblik dodatne soli L-mliječne kiseline karakterizirana XRPD na 5.33, 9.75, 10.10, 14.44 i 14.63 (°2Ѳ).
11. Uporaba u skladu s patentnim zahtjevom 6, pri čemu je navedena sol dodatna sol D-mliječne kiseline.
12. Uporaba u skladu s bilo kojim od patentnih zahtjeva 6-11, pri čemu navedena tekuća formulacija obuhvaća iznad 2.5 mg/mL navedene soli.
13. Sol 1-[2-(2,4 dimetilfenilsulfanil)fenil]piperazina izabrane između dodatka soli DL-mliječne kiseline, dodatka soli L-mliječne kiseline i dodatka soli D-mliječne kiseline za liječenje bolesti odabrane između poremećaja raspoloženja; značajnog depresivnog poremećaja; općeg anksioznog poremećaja; paničnog poremećaja; posttraumatskog stresnog poremećaja; depresije povezane s kognitivnim nedostatkom, Alzheimerove bolesti ili tjeskobe; depresije s ostatnim simptomima; kronične boli; poremećaja ili zlouporabe prehrane, pri čemu je navedena sol u tekućoj farmaceutskoj formulaciji.
14. Sol u skladu s patentnim zahtjevom 13, pri čemu je navedena sol dodatna sol DL-mliječne kiseline.
15. Sol u skladu s patentnim zahtjevom 13, pri čemu je navedena sol dodatna sol L-mliječne kiseline.
16. Sol u skladu s patentnim zahtjevom 13, pri čemu je sol dodatna sol D-mliječne kiseline.
17. Sol u skladu s bilo kojim od patentnih zahtjeva 13-16, pri čemu navedena tekuća formulacija obuhvaća iznad 2.5 mg/mL navedene soli.
18. Tvar koja je sol 1-[2-(2,4 dimetilfenilsulfanil)fenil]piperazina dodatkom L-mliječne kiseline.
19. Tvar u skladu s patentnim zahtjevom 18 koja je MH 2 oblik dodatne soli L-mliječne kiseline karakterizirana XRPD na 5.33, 9.75, 10.10, 14.44 i 14.63 (°2Ѳ).
20. Tvar koja je sol 1-[2-(2,4 dimetilfenilsulfanil)fenil]piperazina dodatkom D-mliječne kiseline.
21. Tvar koja je β oblik dodatne soli DL-mliječne kiseline karakterizirana XRPD refleksijama na 6.01, 10.10, 10.32, 12.06, 12.84, 13.08 i 13.58 (°2Ѳ).
22. Spremnik postavljen s kapljicom agregata, spremnik koji obuhvaća tekuću formulaciju u skladu s bilo kojim od patentnih zahtjeva 1-5.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21454009P | 2009-04-24 | 2009-04-24 | |
| DKPA200900531 | 2009-04-24 | ||
| PCT/DK2010/050084 WO2010121621A1 (en) | 2009-04-24 | 2010-04-16 | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140880T1 true HRP20140880T1 (hr) | 2014-11-07 |
Family
ID=42669509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140880AT HRP20140880T1 (hr) | 2009-04-24 | 2014-09-15 | Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US8940746B2 (hr) |
| EP (1) | EP2421534B1 (hr) |
| JP (1) | JP5722879B2 (hr) |
| KR (1) | KR101779214B1 (hr) |
| CN (2) | CN102405048A (hr) |
| AR (2) | AR076400A1 (hr) |
| AU (1) | AU2010238946B2 (hr) |
| BR (1) | BRPI1015338C1 (hr) |
| CA (1) | CA2759456C (hr) |
| CL (1) | CL2011002631A1 (hr) |
| CO (1) | CO6450649A2 (hr) |
| CR (1) | CR20110554A (hr) |
| DK (1) | DK2421534T3 (hr) |
| DO (2) | DOP2011000319A (hr) |
| EA (1) | EA021122B1 (hr) |
| ES (1) | ES2512719T3 (hr) |
| GE (1) | GEP20135938B (hr) |
| HK (1) | HK1206732A1 (hr) |
| HR (1) | HRP20140880T1 (hr) |
| IL (1) | IL215362A0 (hr) |
| MA (1) | MA33298B1 (hr) |
| MX (1) | MX2011011119A (hr) |
| MY (1) | MY155288A (hr) |
| NZ (1) | NZ596431A (hr) |
| PL (1) | PL2421534T3 (hr) |
| PT (1) | PT2421534E (hr) |
| RS (1) | RS53539B1 (hr) |
| SG (1) | SG175124A1 (hr) |
| SI (1) | SI2421534T1 (hr) |
| SM (1) | SMT201400159B (hr) |
| TN (1) | TN2011000504A1 (hr) |
| TW (1) | TWI461224B (hr) |
| UA (1) | UA106985C2 (hr) |
| WO (1) | WO2010121621A1 (hr) |
| ZA (1) | ZA201107731B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2421534T3 (pl) | 2009-04-24 | 2014-12-31 | H Lundbeck As | Ciekłe preparaty soli 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny |
| WO2014044721A1 (en) * | 2012-09-19 | 2014-03-27 | Sandoz Ag | Novel crystalline form of vortioxetine hydrobromide |
| CA2916175A1 (en) | 2013-07-01 | 2015-01-08 | Lek Pharmaceuticals D.D. | 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form |
| CN106103418A (zh) | 2014-01-31 | 2016-11-09 | 埃吉斯药物私人有限公司 | 沃替西汀盐的制备方法 |
| CN104146953A (zh) * | 2014-07-24 | 2014-11-19 | 李雪梅 | 一种氢溴酸沃替西汀注射液 |
| CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
| CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
| GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| WO2016125190A2 (en) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof |
| JO3456B1 (ar) | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
| DK3414216T3 (da) | 2016-02-08 | 2021-01-25 | Aaa Chemistry Aps | Arylering af alifatiske aminer |
| KR20190025556A (ko) | 2016-07-01 | 2019-03-11 | 하. 룬드벡 아크티에셀스카브 | 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법 |
| CN106518807A (zh) * | 2016-09-17 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 乳酸沃替西汀晶型的制备方法 |
| US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
| CN107011289A (zh) * | 2017-03-10 | 2017-08-04 | 万全万特制药（厦门）有限公司 | 沃替西汀β晶型的制备方法 |
| GB2564887A (en) * | 2017-07-26 | 2019-01-30 | Azad Pharmaceutical Ingredients Ag | New route of synthesis to vortioxetine salts |
| JP2023520016A (ja) | 2020-04-03 | 2023-05-15 | ハー・ルンドベック・アクチエゼルスカベット | 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| AU2004226838B8 (en) | 2003-04-04 | 2009-06-11 | H. Lundbeck A/S | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
| WO2007144006A1 (en) * | 2006-06-16 | 2007-12-21 | H. Lundbeck A/S | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| PL2044043T5 (pl) * | 2006-06-16 | 2022-05-02 | H. Lundbeck A/S | Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych |
| TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TWI405588B (zh) * | 2007-03-20 | 2013-08-21 | Lundbeck & Co As H | ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物 |
| PL2421534T3 (pl) | 2009-04-24 | 2014-12-31 | H Lundbeck As | Ciekłe preparaty soli 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny |
-
2010
- 2010-04-16 PL PL10714164T patent/PL2421534T3/pl unknown
- 2010-04-16 BR BRPI1015338A patent/BRPI1015338C1/pt active IP Right Grant
- 2010-04-16 US US13/265,564 patent/US8940746B2/en active Active
- 2010-04-16 DK DK10714164.0T patent/DK2421534T3/da active
- 2010-04-16 RS RSP20140505 patent/RS53539B1/en unknown
- 2010-04-16 PT PT107141640T patent/PT2421534E/pt unknown
- 2010-04-16 NZ NZ596431A patent/NZ596431A/xx unknown
- 2010-04-16 CA CA2759456A patent/CA2759456C/en active Active
- 2010-04-16 KR KR1020117025009A patent/KR101779214B1/ko active IP Right Grant
- 2010-04-16 MX MX2011011119A patent/MX2011011119A/es active IP Right Grant
- 2010-04-16 EA EA201171287A patent/EA021122B1/ru not_active IP Right Cessation
- 2010-04-16 MY MYPI2011004813A patent/MY155288A/en unknown
- 2010-04-16 CN CN2010800171058A patent/CN102405048A/zh active Pending
- 2010-04-16 ES ES10714164.0T patent/ES2512719T3/es active Active
- 2010-04-16 TW TW099111946A patent/TWI461224B/zh active
- 2010-04-16 CN CN201510093852.4A patent/CN104693145A/zh active Pending
- 2010-04-16 EP EP10714164.0A patent/EP2421534B1/en active Active
- 2010-04-16 SI SI201030759T patent/SI2421534T1/sl unknown
- 2010-04-16 MA MA34385A patent/MA33298B1/fr unknown
- 2010-04-16 WO PCT/DK2010/050084 patent/WO2010121621A1/en active Application Filing
- 2010-04-16 JP JP2012506342A patent/JP5722879B2/ja active Active
- 2010-04-16 SG SG2011073384A patent/SG175124A1/en unknown
- 2010-04-16 GE GEAP201012423A patent/GEP20135938B/en unknown
- 2010-04-16 UA UAA201113335A patent/UA106985C2/uk unknown
- 2010-04-16 AU AU2010238946A patent/AU2010238946B2/en active Active
- 2010-04-23 AR ARP100101364A patent/AR076400A1/es not_active Application Discontinuation
-
2011
- 2011-09-25 IL IL215362A patent/IL215362A0/en active IP Right Grant
- 2011-10-07 TN TNP2011000504A patent/TN2011000504A1/en unknown
- 2011-10-19 CR CR20110554A patent/CR20110554A/es unknown
- 2011-10-20 DO DO2011000319A patent/DOP2011000319A/es unknown
- 2011-10-21 ZA ZA2011/07731A patent/ZA201107731B/en unknown
- 2011-10-21 CL CL2011002631A patent/CL2011002631A1/es unknown
- 2011-10-24 CO CO11143307A patent/CO6450649A2/es active IP Right Grant
-
2012
- 2012-07-27 DO DO2012000211A patent/DOP2012000211A/es unknown
-
2014
- 2014-09-15 HR HRP20140880AT patent/HRP20140880T1/hr unknown
- 2014-10-29 SM SM201400159T patent/SMT201400159B/xx unknown
- 2014-12-11 US US14/567,003 patent/US9475748B2/en active Active
-
2015
- 2015-07-29 HK HK15107256.7A patent/HK1206732A1/xx unknown
-
2016
- 2016-09-21 US US15/271,543 patent/US10034876B2/en active Active
-
2018
- 2018-06-27 US US16/020,799 patent/US10857149B2/en active Active
-
2021
- 2021-05-10 AR ARP210101276A patent/AR122051A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140880T1 (hr) | Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina | |
| JP2010529118A5 (hr) | ||
| HRP20120144T4 (hr) | Terapijske uporabe spojeva koji imaju i sert i 5-ht3 i 5-ht1a aktivnost | |
| HRP20120558T1 (hr) | Kapa-selektivni antagonist opioidnih receptora | |
| BR112012013093A2 (pt) | ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável | |
| AR079542A1 (es) | Derivados de benzamida sustituidos, proceso para su preparacion y su uso en el tratamiento de enfermedades mediadas por taars. | |
| BR112013024312A2 (pt) | derivados de amina heterocíclica | |
| JP2014526435A5 (hr) | ||
| HRP20201405T1 (hr) | Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a | |
| JP2015521642A5 (hr) | ||
| AR086880A1 (es) | Derivados de morfolin-benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de las mismas para tratar enfermedades asociadas fundamentalmente al sistema nervioso central | |
| HRP20110844T1 (hr) | Tekući oblici soli 4-[2-(4-metilfenilsulfanil)fenil]piperidina | |
| RU2015111836A (ru) | Производные триазолкарбоксамида | |
| JP2012528824A5 (hr) | ||
| RU2016146560A (ru) | Производные морфолин-пиридина | |
| HRP20120344T1 (hr) | N-(2-hidroksietil)-n-metil-4-(kinolin-8-il(1-(tiazol-4-ilmetil) piperidin-4-iliden)metil)benzamid, postupak njegovog dobivanja kao i njegova uporaba za liječenje bola, tjeskobe i depresije | |
| PH12015500489B1 (en) | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease | |
| BRPI0514820A (pt) | antagonistas de receptor de histamina-3 amina azabicìclicos | |
| SI3149002T1 (en) | 5-Oxa-2-azabicyclo (2.2.2) octan-4-yl and 5-oxa-2-azabicyclo (2.2.1) heptan-4-yl derivatives as TAAR1 receptor modulators | |
| JP2015521643A5 (hr) | ||
| BR112013010558A2 (pt) | derivados de di-hidro-oxazol-2-amina | |
| JP2007520537A5 (hr) | ||
| FI2421534T5 (fi) | 1-[2-(2,4-dimetyylifenyylisulfanyyli)fenyyli]piperatsiinin suolojen nestemäiset formulaatiot | |
| JP2010505919A5 (hr) | ||
| AR076979A1 (es) | 2- aminooxazolinas como ligandos de taar1 |